App-Quantinova.ai

Efficacy of Mesenchymal Stromal Cells for Refractory Late-Onset Hemorrhagic Cystitis after Allogeneic Hematopoietic Stem Cell Transplantation

Ke Zhao - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Cytomegalovirus infection

Allopurinol

First-Line Consolidation Therapy with CD19/CD22 Bispecific CAR-T Cells for MRD Positive B-ALL Maybe Feasible

Xianmin Song - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

B-cell acute lymphoblastic leukemia

Prednisone

The Efficacy of Residual Plerixafor of Second-Day Stem Cell Mobilization in Multiple Myeloma Patients

Donghua He - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Plerixafor

Application of Metagenomic Next Generation Sequencing in the Diagnosis of Pulmonary Infectious Pathogens from Bronchoalveolar Lavage Samples in Patients Underwent Allogeneic Hematopoietic Stem Cell Transplantation

Jian Yu - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Allopurinol

Decitabine Combined with FB3 As Conditional Regimen for Elderly/Weak Acute Myeloid Leukemia Patient with Allo-HSCT

Shichun Gao - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

fludarabine tablet

Long-Term Efficacy Analysis of Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Acute Myeloid Leukemia Using Melphalan Instead of Cyclophosphamide As a Myeloablative Conditioning Regimen

Ying Zhang - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Graft-versus-host disease

Mycophenolate mofetil

Haploidentical Stem Cell Transplantation Had a Lower Incidence of Bronchiolitis Obliterans Syndrome Compared with HLA-Matched Sibling Transplantation for Patients with Hematologic Malignancies: Benefit from ATG?

Guangyang Weng - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Obliterative bronchiolitis

N/A

Post-Transplantation Cyclophosphamide Combined with Tacrolimus and Low-Dose Post-Engraftment Anti-Thymoglobulin As Gvhd Prophylaxis for Patients Undergoing Peripheral Blood Stem Cell Transplantation from Haplo Donors: A Single Center Analysis

Jiong Hu - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Graft-versus-host disease

Cyclophosphamide

The Efficacy and Safety of Ruxolitinib in Steroid-Refractory Graft-Versus-Host Disease in Chinese Patients: Systematic Review and Meta-Analysis

Xu Yang - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Graft-versus-host disease

Ruxolitinib phosphate

The Lack of Functional DNMT2 Gene Modulates Gvhd Process Via tRNA m5c Modification

Huanping Guo - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Graft-versus-host disease

Allopurinol

The OTUD1-Notch2-ICD Axis Orchestrates Allogeneic T Cell-Mediated Graft-Versus-Host Disease

Qiao Cheng - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Graft-versus-host disease

Dapagliflozin

Single-Cell Immune Landscape of Measurable Residual Disease in AML after Allogeneic Hematopoietic Stem Cell Transplantation

Xiao-Dong Mo - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

Allopurinol

Risk Factors and Prediction Model of Early Relapse in Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation

Xiaolin Yuan - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

Allopurinol

High-Dose Idarubicin Plus Busulfan As Conditioning Regimen to Autologous Stem Cell Transplantation Improves Prognosis in Patients with Favorable and Intermediate-Risk AML

Ming Hong - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Cytarabine liposomal

Efficacy and Safety of Azacytidine Combined with Low-Dose Lenalidomide in Preemptive Treatment of Post Allo-SCT Acute Myeloid Leukemia Patients with Detectable Minimal Residual Disease

Lu Wang - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Graft-versus-host disease

Lenalidomide

Efficacy and Safety of Tandem Autologous Stem Cell Transplantation in Multiple Myeloma: A Retrospective Single-Center Analysis in China

Shunquan Wu - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

N/A

Comparison of Hematopoietic Stem Cell Transplantation and Immunosuppressive Therapy for Patients with Severe Hepatitis-Associated Aplastic Anemia

Xiaoyu Zhang - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Aplastic anemia

Cyclophosphamide

Comparison of ATG-Based Immunosuppressive Treatment and Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Transfusion-Dependent Non-Severe Aplastic Anemia: A Single Center, Retrospective Analysis

Yuzhu Li - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Graft-versus-host disease

Cyclosporine eent

Autologous Versus Haploidentical Stem Cell Transplantation in Adult Patients with Intermediate Risk Actue Myelogenous Leukemia in First Complete Remission and Undetectable Minimal Residual Disease: A Global Preliminary Analysis of Chinese Data

Jia Chen - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Graft-versus-host disease

N/A

Short-Term Efficacy and Safety of Haplo Hematopoietic Stem Cell Transplantation for Refractory and/or Relapsed Leukemia

Wei Zhao - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Cyclophosphamide

Filters

24782 Abstracts